-
1
-
-
79951494668
-
Initial genome sequencing and analysis of multiple myeloma
-
Chapman MA, et al. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471(7339):467-472.
-
(2011)
Nature
, vol.471
, Issue.7339
, pp. 467-472
-
-
Chapman, M.A.1
-
2
-
-
64749098712
-
Multiple myeloma: Biology, standard therapy, and transplant therapy
-
Gertz MA, Ghobrial I, Luc-Harousseau J (2009) Multiple myeloma: Biology, standard therapy, and transplant therapy. Biol Blood Marrow Transplant 15(1, Suppl):46-52.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, Issue.1
, pp. 46-52
-
-
Gertz, M.A.1
Ghobrial, I.2
Luc-Harousseau, J.3
-
3
-
-
67349241955
-
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
-
Peterson TR, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137(5):873-886.
-
(2009)
Cell
, vol.137
, Issue.5
, pp. 873-886
-
-
Peterson, T.R.1
-
5
-
-
48549094467
-
C-Myc and eIF4F are components of a feedforward loop that links transcription and translation
-
Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J (2008) c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 68(13): 5326-5334.
-
(2008)
Cancer Res
, vol.68
, Issue.13
, pp. 5326-5334
-
-
Lin, C.J.1
Cencic, R.2
Mills, J.R.3
Robert, F.4
Pelletier, J.5
-
6
-
-
0034602691
-
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
-
Shou Y, et al. (2000) Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 97(1):228-233.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, Issue.1
, pp. 228-233
-
-
Shou, Y.1
-
7
-
-
79958095463
-
Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma
-
Chng WJ, et al. (2011) Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25(6):1026-1035.
-
(2011)
Leukemia
, vol.25
, Issue.6
, pp. 1026-1035
-
-
Chng, W.J.1
-
8
-
-
32844456419
-
Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis
-
Kanungo A, Medeiros LJ, Abruzzo LV, Lin P (2006) Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 19(1):25-33.
-
(2006)
Mod Pathol
, vol.19
, Issue.1
, pp. 25-33
-
-
Kanungo, A.1
Medeiros, L.J.2
Abruzzo, L.V.3
Lin, P.4
-
9
-
-
0027289462
-
Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc
-
Rosenwald IB, Rhoads DB, Callanan LD, Isselbacher KJ, Schmidt EV (1993) Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci USA 90(13):6175-6178.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, Issue.13
, pp. 6175-6178
-
-
Rosenwald, I.B.1
Rhoads, D.B.2
Callanan, L.D.3
Isselbacher, K.J.4
Schmidt, E.V.5
-
10
-
-
1642586272
-
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
-
Wendel HG, et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332-337.
-
(2004)
Nature
, vol.428
, Issue.6980
, pp. 332-337
-
-
Wendel, H.G.1
-
11
-
-
80053203115
-
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma
-
Gera J, Lichtenstein A (2011) The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk Lymphoma 52(10):1857-1866.
-
(2011)
Leuk Lymphoma
, vol.52
, Issue.10
, pp. 1857-1866
-
-
Gera, J.1
Lichtenstein, A.2
-
12
-
-
10244260355
-
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
-
Raje N, et al. (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104(13):4188-4193.
-
(2004)
Blood
, vol.104
, Issue.13
, pp. 4188-4193
-
-
Raje, N.1
-
13
-
-
27644534999
-
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
-
Shi Y, Yan H, Frost P, Gera J, Lichtenstein A (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4(10):1533-1540.
-
(2005)
Mol Cancer Ther
, vol.4
, Issue.10
, pp. 1533-1540
-
-
Shi, Y.1
Yan, H.2
Frost, P.3
Gera, J.4
Lichtenstein, A.5
-
14
-
-
67650995912
-
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
-
McMillin DW, et al. (2009) Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 69(14):5835-5842.
-
(2009)
Cancer Res
, vol.69
, Issue.14
, pp. 5835-5842
-
-
McMillin, D.W.1
-
15
-
-
78649471733
-
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
-
Hoang B, et al. (2010) Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116(22):4560-4568.
-
(2010)
Blood
, vol.116
, Issue.22
, pp. 4560-4568
-
-
Hoang, B.1
-
16
-
-
84880352272
-
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
-
Pourdehnad M, et al. (2013) Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci USA 110(29):11988-11993.
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, Issue.29
, pp. 11988-11993
-
-
Pourdehnad, M.1
-
17
-
-
17444440115
-
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
-
Strömberg T, et al. (2004) Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103(8):3138-3147.
-
(2004)
Blood
, vol.103
, Issue.8
, pp. 3138-3147
-
-
Strömberg, T.1
-
18
-
-
33644516582
-
Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis
-
Yan H, et al. (2006) Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 66(4):2305-2313.
-
(2006)
Cancer Res
, vol.66
, Issue.4
, pp. 2305-2313
-
-
Yan, H.1
-
19
-
-
0038824960
-
How myeloma cells escape bisphosphonate- mediated killing: Development of specific resistance with preserved sensitivity to conventional chemotherapeutics
-
Salomo M, Jurlander J, Nielsen LB, Gimsing P (2003) How myeloma cells escape bisphosphonate- mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol 122(2):202-210.
-
(2003)
Br J Haematol
, vol.122
, Issue.2
, pp. 202-210
-
-
Salomo, M.1
Jurlander, J.2
Nielsen, L.B.3
Gimsing, P.4
-
20
-
-
0031415218
-
A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death
-
D'Adamio F, et al. (1997) A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 7(6): 803-812.
-
(1997)
Immunity
, vol.7
, Issue.6
, pp. 803-812
-
-
D'adamio, F.1
-
21
-
-
0031982683
-
A novel functional human eukaryotic translation initiation factor 4G
-
Gradi A, et al. (1998) A novel functional human eukaryotic translation initiation factor 4G. Mol Cell Biol 18(1):334-342.
-
(1998)
Mol Cell Biol
, vol.18
, Issue.1
, pp. 334-342
-
-
Gradi, A.1
-
22
-
-
0032834055
-
EIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation
-
Gingras AC, Raught B, Sonenberg N (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963.
-
(1999)
Annu Rev Biochem
, vol.68
, pp. 913-963
-
-
Gingras, A.C.1
Raught, B.2
Sonenberg, N.3
-
23
-
-
84862520790
-
A cellular response linking eIF4AI activity to eIF4AII transcription
-
Galicia-Vázquez G, Cencic R, Robert F, Agenor AQ, Pelletier J (2012) A cellular response linking eIF4AI activity to eIF4AII transcription. RNA 18(7):1373-1384.
-
(2012)
RNA
, vol.18
, Issue.7
, pp. 1373-1384
-
-
Galicia-Vázquez, G.1
Cencic, R.2
Robert, F.3
Agenor, A.Q.4
Pelletier, J.5
-
24
-
-
38849180436
-
Targeting the eukaryotic translation initiation factor 4E for cancer therapy
-
Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68(3):631-634.
-
(2008)
Cancer Res
, vol.68
, Issue.3
, pp. 631-634
-
-
Graff, J.R.1
Konicek, B.W.2
Carter, J.H.3
Marcusson, E.G.4
-
25
-
-
84867760869
-
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors
-
Liu T, et al. (2012) Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J Med Chem 55(20):8859-8878.
-
(2012)
J Med Chem
, vol.55
, Issue.20
, pp. 8859-8878
-
-
Liu, T.1
-
26
-
-
65549098672
-
Antitumor activity and mechanism of action of the cyclopenta [b]benzofuran, silvestrol
-
Cencic R, et al. (2009) Antitumor activity and mechanism of action of the cyclopenta [b]benzofuran, silvestrol. PLoS ONE 4(4):e5223.
-
(2009)
PLoS ONE
, vol.4
, Issue.4
, pp. e5223
-
-
Cencic, R.1
-
27
-
-
2342489456
-
EIF-4E expression and its role in malignancies and metastases
-
De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23(18):3189-3199.
-
(2004)
Oncogene
, vol.23
, Issue.18
, pp. 3189-3199
-
-
De Benedetti, A.1
Graff, J.R.2
-
28
-
-
37249042829
-
Dissecting eIF4E action in tumorigenesis
-
Wendel HG, et al. (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21(24): 3232-3237.
-
(2007)
Genes Dev
, vol.21
, Issue.24
, pp. 3232-3237
-
-
Wendel, H.G.1
-
29
-
-
21744457447
-
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
-
Wuillème-Toumi S, et al. (2005) Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19(7):1248-1252.
-
(2005)
Leukemia
, vol.19
, Issue.7
, pp. 1248-1252
-
-
Wuillème-Toumi, S.1
-
30
-
-
0037468570
-
IL-6-independent expression of Mcl-1 in human multiple myeloma
-
Zhang B, Potyagaylo V, Fenton RG (2003) IL-6-independent expression of Mcl-1 in human multiple myeloma. Oncogene 22(12):1848-1859.
-
(2003)
Oncogene
, vol.22
, Issue.12
, pp. 1848-1859
-
-
Zhang, B.1
Potyagaylo, V.2
Fenton, R.G.3
-
31
-
-
84860729291
-
The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
-
Descamps G, et al. (2012) The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br J Cancer 106(10):1660-1667.
-
(2012)
Br J Cancer
, vol.106
, Issue.10
, pp. 1660-1667
-
-
Descamps, G.1
-
32
-
-
80053070033
-
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
-
Ilic N, Utermark T, Widlund HR, Roberts TM (2011) PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA 108(37):E699-E708.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, Issue.37
, pp. E699-E708
-
-
Ilic, N.1
Utermark, T.2
Widlund, H.R.3
Roberts, T.M.4
-
33
-
-
0029807699
-
Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines
-
Hala M, Hartmann BL, Böck G, Geley S, Kofler R (1996) Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines. Int J Cancer 68(5):663-668.
-
(1996)
Int J Cancer
, vol.68
, Issue.5
, pp. 663-668
-
-
Hala, M.1
Hartmann, B.L.2
Böck, G.3
Geley, S.4
Kofler, R.5
-
34
-
-
0022516366
-
Glucocorticoid receptors and glucocorticoid resistance in human leukemia in vivo and in vitro
-
Thompson EB, Harmon JM (1986) Glucocorticoid receptors and glucocorticoid resistance in human leukemia in vivo and in vitro. Adv Exp Med Biol 196:111-127.
-
(1986)
Adv Exp Med Biol
, vol.196
, pp. 111-127
-
-
Thompson, E.B.1
Harmon, J.M.2
-
35
-
-
0035187441
-
Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: Importance of the ligand-binding domain for intracellular GR trafficking
-
Kino T, Stauber RH, Resau JH, Pavlakis GN, Chrousos GP (2001) Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: Importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab 86(11):5600-5608.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, Issue.11
, pp. 5600-5608
-
-
Kino, T.1
Stauber, R.H.2
Resau, J.H.3
Pavlakis, G.N.4
Chrousos, G.P.5
-
36
-
-
33846187629
-
Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells
-
Sánchez-Vega B, Krett N, Rosen ST, Gandhi V (2006) Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Ther 5(12): 3062-3070.
-
(2006)
Mol Cancer Ther
, vol.5
, Issue.12
, pp. 3062-3070
-
-
Sánchez-Vega, B.1
Krett, N.2
Rosen, S.T.3
Gandhi, V.4
-
37
-
-
33749443714
-
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
-
Wei G, et al. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10(4):331-342.
-
(2006)
Cancer Cell
, vol.10
, Issue.4
, pp. 331-342
-
-
Wei, G.1
|